Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Tom R. Clarksburg who wrote (510)	5/4/1998 12:56:00 PM
From: David Winkler	Read Replies (2) \| Respond to of 2135

This was cut from post 344 this site: ENMD receives orphan drug designation... ROCKVILLE, Md.--(BW HealthWire)--March 3, 1998--EntreMed Inc. (Nasdaq: ENMD) today announced that it has received orphan drug designation from The Food and Drug Administration (FDA) for thalidomide as a treatment for primary brain malignancies. If the FDA ultimately approves the use of thalidomide for this indication, orphan drug designation will entitle EntreMed to exclusive marketing rights for the use of thalidomide in the treatment of primary brain malignancies for a seven-year period.... Comments? This says it all!!!!

To: Tom R. Clarksburg who wrote (510)	5/4/1998 2:08:00 PM
From: LTK007	Read Replies (3) \| Respond to of 2135

Tom, shark cartilage cure up to now has been all anectodal hype,there has yet to be be any hard scientific evidence that it really works. With angiostatin/endostatin we have a treatment that has passed a critical crossroads with hard science tests in mice.And not just the anectodal hype,that shark's cartilage gets--that is my view,unless can back up your "Pure , clinical grade Shark cartilage has also been tested in clinical trials in several leading U.S. and worldwide hospitals with tremendous preliminary results." I will hold my suspicion of shark cartilage treatment until proven wrong.max90

To: Tom R. Clarksburg who wrote (510)	5/4/1998 5:14:00 PM
From: StockDoc	Respond to of 2135

Tom R. Clarksburg, it's indeed not new. Folkman works on this concept for 25+ years, and the fruits of his team's work are, among others, ES and AS. As of Thalidomide, guess who's working on it: ENMD. As of shark cartilage: here's the poor man's recipe: Take 2 pounds of shark, with fins.(Cook it - optional). Eat it (with cartilage - it's entirely edible). You'll get the material cheaper than any "pharmaceutical grade" material. It may even work. It's big not just in Cuba, in China, too. Why many die from liver cancer irrespective of the amount of shark cartilage (fins, bones, etc.) consumed daily, is a mystery. StockDoc

To: Tom R. Clarksburg who wrote (510)	5/4/1998 7:00:00 PM
From: BARRY ALLEN	Read Replies (2) \| Respond to of 2135

Ever hear of Advanced Viral Research(ADVR)? Their flagship drug, Reticulose, is also under study by the NCI. Here is an excerpt of that announcement. They are already doing PhaseIII human trials in Argentina on AIDS and Herpes/HPV! "Reticulose is a non-toxic immunomodulator that has been shown to have a broad spectrum of antiviral therapeutic effects in patients. At the NCI, Reticulose is being used to study the basic mechanisms of immune responses. This scientific research is led by Dr. Howard Young, Section Chief in the Laboratory of Experimental Immunology at the NCI, an expert on interferon-gamma. Using kidney tumor model systems, Dr. Young is investigating the anti-tumor activity of Reticulose. In addition, Dr. Young and his colleagues will study the effects of Reticulose on inflammation associated with rheumatoid arthritis." biz.yahoo.com